Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

Oxford/AstraZeneca vaccine results face growing scrutiny

Oxford/AstraZeneca vaccine results face growing scrutiny

Share price drops as critics question claim vaccine could protect up to 90% of people
The Oxford University/AstraZeneca vaccine will undergo a new global trial as critics questioned the claim that it could protect up to 90% of people against coronavirus.

On Thursday Sir John Bell, Oxford’s regius professor of medicine and the UK government’s life sciences adviser, dismissed suggestions the previous trial had not been properly set up or reported. “We weren’t cooking this up as we went along,” he said, adding that he hoped the full, peer-reviewed data would be published in the Lancet medical journal at the weekend.

In spite of the public excitement generated by the announcement that a third vaccine had been successful – with particular promise for developing countries as it is relatively cheap and can be stored at fridge temperature – AstraZeneca’s share price dropped.

One analyst in the US wrote in an investor note that “we believe that this product will never be licensed in the US” and alleged the company had tried to “embellish” the results.

It comes after the headline figure for the vaccine’s overall efficacy was put at 70% – as announced by the company on Monday and discussed in a press briefing by the Oxford researchers. But a sub-set of fewer than 3,000 people in the UK was given a lower dose regime – originally by accident – where the efficacy rose to 90%. In most trial volunteers in Brazil and the UK, it was 62%.

Sir Mene Pangalos, AstraZeneca’s head of biopharmaceuticals R&D, has confirmed that the low-dose trial included nobody over the age of 55. This led to concerns that younger age may have been a factor – particularly relevant given that vulnerable elderly people are most at risk from Covid-19.

Researchers had no explanation for the 90% result in people given a half dose followed by a whole dose of the vaccine, instead of two whole doses in other arms of the trial.

On Thursday AstraZeneca said it would undertake a new global trial using the lower-dose regimen. The timeline for regulatory approval and rollout of the vaccine in the UK and Europe should not be affected.

Critics have also claimed the trials did not include enough ethnic diversity, gender and age balance to satisfy the US regulator, the Food and Drug Administration.

Defending the vaccine trials, Bell told a symposium run by the Faculty of Pharmaceutical Medicine: “[The] MHRA [Medicines and Healthcare Products Regulatory Authority] knew perfectly well what we were doing. They approved all the protocols.”

It had been widely accepted before any of the vaccine trials reported results that 60% efficacy would be enough for a licence and would be useful, he said. “We are well in excess of that. I can’t imagine any reason why regulators won’t accept that.”

America had not yet seen the full data, he said, which he hoped would be published in the Lancet at the weekend. “I think when they see the data, it will be a great deal easier to have these conversations.”

Scientists at Oxford and the company admitted they were surprised by the finding that a lower dosing regime got better results. Pangalos called it serendipity.

“It could be that by giving a small amount of the vaccine to start with and following up with a big amount, that’s a better way of kicking the immune system into action and giving us the strongest immune response and the most effective immune response,” said Prof Sarah Gilbert, who led the vaccine research at Oxford.

AstraZeneca’s CEO told Bloomberg it would begin an international trial using the lower-dose regimen, while previously it had been expected merely to add an arm to the existing trial in the US.

The move will be seen as a bid to satisfy the FDA and compete, if they do win a licence in the US, with Pfizer and Moderna which have both published data suggesting 95% efficacy.

“Now that we’ve found what looks like a better efficacy [in the half dose/full dose regime], we have to validate this, so we need to do an additional study,” CEO Pascal Soriot said on Thursday. The study would probably be global “but this one could be faster because we know the efficacy is high so we need a smaller number of patients”.

Peter Openshaw, professor of experimental medicine at Imperial College London, said more data would need to be collected if the low-dose arm of the trial included only under-55s.

“If this is true, it may mean we don’t have any information about this regimen in older adults,” he said. “We have to wait for the full data and to see how the regulators view the results of the phase 3 trials. The US and European regulators might possibly take a different view. All we have to go on is a limited data release.”

It was possible, he said, that the protection from the Oxford/AstraZeneca vaccine might be less than that from the Pfizer/BioNTech and Moderna vaccines, which were developed with a different technology based on RNA, “but we need to wait and see”.

Paul Hunter, professor in medicine at the University of East Anglia and an adviser on methodology to the World Health Organization, said he was always wary of sub-group analyses in trials.

“Most of the time when you get these incredibly good results in a sub-group analysis, you have to be incredibly careful about believing them,” he told the Guardian. There could be something about the smaller group that was not true of the larger group.

He was also worried by the suggestion the sub-group had nobody over 55. “I’m not saying this isn’t going to be a fantastic vaccine at the end of the day, but we need a lot better understanding of the data,” he said.

An AstraZeneca spokesperson said an independent data safety monitoring board ensures the safety and quality of the trials. “The studies were conducted to the highest standards,” it said in a statement. “More data will continue to accumulate and additional analysis will be conducted refining the efficacy reading and establishing the duration of protection.”
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
Severe Heatwave Claims 2,300 Lives Across Europe
Declining Beer Consumption Signals Cultural Shift in Germany
Emails Leaked: How Passenger Luggage Became a Side Income for Airport Workers
Polish MEP: “Dear Leftists - China is laughing at you, Russia is laughing, India is laughing”
Western Europe Records Hottest June on Record
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
China’s Central Bank Consults European Peers on Low-Rate Strategies
France Requests Airlines to Cut Flights at Paris Airports Amid Planned Air Traffic Controller Strike
Poland Implements Border Checks Amid Growing Migration Tensions
Emirates Airline Expands Market Share with New $20 Million Campaign
Amazon Reaches Milestone with Deployment of One Millionth Robot
Yulia Putintseva Calls for Spectator Ejection at Wimbledon Over Safety Concerns
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
Amazon Reaches Major Automation Milestone with Over One Million Robots
Extreme Heat Wave Sweeps Across Europe, Hitting Record Temperatures
Meta Announces Formation of Ambitious AI Unit, Meta Superintelligence Labs
Robots Compete in Football Tournament in China Amid Injuries
China Unveils Miniature Insect-Like Surveillance Drone
Marc Marquez Claims Victory at Dutch Grand Prix Amidst Family Misfortune
Germany Votes to Suspend Family Reunification for Asylum Seekers
Budapest Pride Parade Draws 200,000 Participants Amid Government Ban
Southern Europe Experiences Extreme Heat
Xiaomi's YU7 SUV Launch Garners Record Pre-Orders Amid Market Challenges
Jeff Bezos and Lauren Sanchez's Lavish Wedding in Venice
Russia Launches Largest Air Assault on Ukraine Since Invasion
Massive Anti-Government Protests Erupt in Belgrade
Iran Executes Alleged Israeli Spies and Arrests Hundreds Amid Post-War Crackdown
Hungary's Prime Minister Criticizes NATO's Role in Ukraine
EU TO HUNGARY: LET THEM PRIDE OR PREP FOR SHADE. ORBÁN TO EU: STAY IN YOUR LANE AND FIX YOUR OWN MESS.
Hungarian Scientist to Conduct 30 Research Experiments on the International Space Station
NATO Members Agree to 5% Defense Spending Target by 2035
NATO Leaders Endorse Plan for Increased Defence Spending
U.S. Crude Oil Prices Drop Below $65 Amid Market Volatility
International Astronaut Team Launched to Space Station
Macron and Merz: Europe must arm itself in an unstable world
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Iran Intensifies Crackdown on Alleged Mossad Operatives After Sabotage Claims
Trump Praises Iran’s ‘Very Weak’ Response After U.S. Strikes and Presses Israel to Pursue Peace
Oil Prices Set to Surge After US Strikes Iran
BA and Singapore Airlines Cancel Dubai Flights Amid Middle East Tensions
Trump Faces Backlash from MAGA Base Over Iran Strikes
Meta Bets $14 B on Alexandr Wang to Drive AI Ambitions
FedEx Founder Fred Smith, ‘Heart and Soul’ of the Company, Dies at 80
Chinese Factories Shift Away from U.S. Amid Trump‑Era Tariffs
Pimco Seizes Opportunity in Japan’s Dislocated Bond Market
Labubu Doll Drives Pop Mart to Status as China’s Most Valuable Toy Maker
Global Coal Demand Defies Paris Accord Goals
United States Conducts Precision Strikes on Iran’s Nuclear Sites
US strikes Iran nuclear sites, Trump says
×